BioSpace News Archive

Edgewise Therapeutics, Inc. announced today that management will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2023, at 10 am PT (1 pm ET).

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it mandated Transbiotech Biotechnology Research

OKYO Pharma Limited is pleased to announce that patients are now being dosed in the randomized portion of the phase 2, multi-center, double-masked, placebo-controlled trial of topical ocular OK-101 to treat DED.

Curative Biotechnology Inc., a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset licensing within the country.

Astria Therapeutics, Inc. granted stock options to purchase 20,000 shares of Astria’s common stock on June 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

Medtech startup AVATAR MEDICAL announced today that its virtual reality (VR) surgical planning solution has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Vistagen today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty unanimously approved by its Board of Directors.

Brand Institute is proud to announce its work with Lexicon Pharmaceuticals, Inc. in developing the brand name INPEFA™ (sotagliflozin), which was approved by the FDA on May 26, 2023.

StageZero Life Sciences, Ltd. (TSX: SZLS) (“StageZero” or the “Company”) today announced that it will host a conference call as part of its Special and Annual General Meeting of Shareholders on Wednesday June 7, 2023, so that all shareholders may follow along with the proceedings of the meeting.

Replimune Group, Inc. announced initial data from ARTACUS, a Phase 1/2 trial evaluating RP1 for the treatment of cutaneous malignancies in patients who have had a kidney, liver, heart, lung, and/or a hematopoietic cell transplant.